From Bench to Bedside: Secondary Use of Health Data for Precision Medicine

CMEL Conference on Precision Medicine: Legal and Ethical Challenges 7-8 April 2016, HKU



Dr. Chih-hsing Ho Academia Sinica Taipei, Taiwan chihho@sinica.edu.tw





" Translational research includes two areas of translation. One (T1) is the process of applying discoveries generated during research in the laboratory, and in preclinical studies, to the development of trials and studies in humans. The second area of translation (T2) concerns research aimed at enhancing the adoption of best practices in the community. Cost-effectiveness of prevention and treatment strategies is also an important part of translational science."

National Institutes of Health (NIH). Definitions under Subsection 1 (Research Objectives), Section I (Funding Opportunity Description), Part II (Full Text of Announcement), of RFA-RM-07-007: Institutional Clinical and Translational Science Award (U54) Mar2007

1. DISCOVERY

2. DEVELOPMENT

3. DELIVERY



CLINICAL TRIALS

Once a disease target is identified, drugs are designed and tested. Both public and privately funded research are involved.

REGULATORY APPROVAL

Human trials are completed. FDA approval. Industry is responsible for bringing a drug to market. Safety and evaluation continue after approvals.

PHASEI PHASEII PHASEIII

BASIC RESEARCH

The majority of the research at this stage is publicly funded at universities, colleges and independent research institutions in every state.

source: www.researchamerica.org

PATIENT CARE

Biobanks (biospecimens +

Health and lifestyle data)

DATA Aggregation Linkage Processing Sharing

Translational Biomedical Research Secondary Use of Health data:

Personal health information (PII) for uses outside of its original purposes of collection



Biobank Infrastructure for the 21st Century - Learning from Taiwan

⁺Belinda KL Chen PhD, ^{*}Vincent Deng, [~]Tyrone Grandison PhD, ^{*}Joe CH Lu PhD, ^{*}Andy Ma, ⁺Chi-Ta Yang

klchen@iii.org.tw, ywdeng@tw.ibm.com, tyroneg@us.ibm.com, joelu@tw.ibm.com, shma@tw.ibm.com, gary1122@iii.org.tw

⁺Institute for Information Industry (III), Innovative DigiTech-Enabled Applications & Services (IDEAS) Institute, 8F., No.133, Sec. 4, Minsheng E. Road., Taipei, Taiwan, ROC *IBM Taiwan, Life Sciences Center of Excellence, 10 F., Bldg. E, 19-13, Sanchong Road, Nankang District, Taipci, Taiwan, ROC

Hara-Lien

15.000

[~]Data Disclosure Research, Healthcare Informatics, IBM Healthcare Center of Excellence, IBM Almaden Research, 650 Harry Road, San Jose, California, USA

Introduction

- The Taiwan government is committed to making Taiwan "The Biomed-Tech Island". This involves three major efforts:
- Taiwan Biobank Project
- National Health Information Project (NHIP)
- Clinical Trial Research

The Taiwan BioBank Project is

 a national effort that will integrate and synergize the public health, biotech, pharmaceutical and healthcare industries in an effort to deliver better healthcare for the Taiwanese people.

The project's goals are:

- To understand descriptive epidemiological features and to obtain background risk
 profiles of common diseases in Taiwan.
- To explore gene-risk factor/gene-gene interactions associated with common diseases.
- To establish essential bio-informatic networks of Biobanks, leading to the development of Bio-IT.
- To explore critical issues related to ethnic, legal, and social issues (ELSI) of genomic medicine and develop solutions for these concerns.

Why is Taiwan ideal for a BioBank effort?


- Relatively Genetically Homogeneous Population.
- High-Quality Medical Care Service.
- Nationwide Health Insurance System.
- Advanced instruments and platforms for clinical diagnosis, genetic and micro-array analysis, biological sample storage, and cell line preservation.
- Strong experience on IT hardware & software development.
- Extensive Logistics Network
 throughout Taiwan.




What is the Project's Scope and Current Status

Pilot study: January 2006 – December 2009 Size of Participants: 15,000 Expected cohort: 200,000 Participants: Residents of: - Mao-Li Country (Fukien & Hukka & Mainland) - Chia-Yi City (Fukien & Mainland) - Hwa-Lien Country (Indigenous & Fukien & Mainland) Aged 40 to 70 Volunteer Current Focus: IT Platform Development.

Data Stored in the Taiwan Biobank



Taiwan Biobank Solution Architecture



Summary of Conclusions

- The Taiwan Biobank provides an amazing leap forward in the enablement of the medical research.
- The commitment from the government, perfect suitability of the country of Taiwan
 and the leveraging of state-of-the art technology to address the privacy and
 interoperability concerns makes a solid foundation for significant breakthrough in
 healthcare research, while allaying public fears.
- The establishment of a comprehensive and secure IT infrastructure that provides integrated tools, services and reliable management of information assets in support of Taiwan Biobank is a significant milestone for the healthcare community.
- The fact that the platform will address the privacy and security issues, raised by the public, and be compliant with policies, standards, and guidelines recommended by Taiwan's Information Technology Advisory Board (ITAB) provides the world with a safe model for biobank construction and use.

Features of Taiwan Biobank

- Biomedical Technology Island Plan (2004): (for health and wealth)
- Funded by the Ministry of Health (around NTD 7,000 millions)
- A prospective population cohort; target 200,000 (healthy population) + 100,000 (affiliated with 13 hospitals, disease samples)
- Executive agency: Institute of Biomedical Sciences (IBMS), Academia Sinica
- To know the causes of diseases (pharmacogenomics -> precision medicine)
- Governance Frameworks
 - Dual Track Governance: IRB + EGC (not only " a critical friend")
 - Guidelinesà Human Biobank Management Act (2010)
 - Personal Data Protection Act (data linkage?)
- IRB: disease samples (data merge: secondary use of data): re-consent? (not yet approved)

Secondary Use of Health Data

- As electronic health records (EHR) are adopted as the standard for clinical practice, new sources of detailed information will be created.
- Aggregated health data provide value to a broad range of research, quality, public health and commercial applications (used for non-clinical applications)
- Yet, access and use of health data pose complex ethical, legal, technical and economic challenges
- E.g., buying and selling of non-anonymized patient and provider data by the medical industry but carried out without explicit consent from patients or physicians

National Health Insurance Database

- NHI Model: mandatory insurance
- Universal coverage
- Enrolment rate: 99% (population: 23 million)



- National Health Insurance Act: the purpose of collection: insurance claims
- Data include
 - (i) personal data: ID no. name, DOB, type of work, insured salary
 (ii) medical data: inpatient/outpatient visit data, length, branch of medicine, diagnosis, prescription, treatment, fee, etc

A Recent Pending Lawsuit in Taiwan

- Taiwan Association for Human Rights (TAHR) vs. National Health Insurance Administration (NHIA)
- Background: 8 plaintiffs claimed for withdraw their national health insurance data from the NHIA (data controller) when they knew that the NHIA sold their personal data (barcoded names & ID, but BOD and prescription info are still available) to the National Health Research Institute (NHRI) for academic research purposes. And, NHRI then sold the data to pharmaceutical companies for academic or non-academic research purposes.
- Issues:

(i) Non-personally identifiable information (PII)?(ii) Under PDA in Taiwan-- if it is not PII, then no need to have consent(iii) no opt-out allowed? (obstacle to research?)


- Pending Decisions:
 - Taipei Local Administrative Court: NHIA won; based on PDA in Taiwan
 - Taipei High Administrative Court: referred back

Laws on consent and data sharing

Human Subjects Research Act	Biobank Management Act	Personal Data Protection Act
 project specific consent Re-consent needed for future research 	- broad consent - Re-consent usually not needed -	Without consent, If the personal information is processed or provided by the information provider in a way that it would not lead to the identification of a certain person
Secondary use of data		Big data challenge ??




Health Cloud Planning in Taiwan



Copyright 2013 ITRI 工業技術研究院

Industrial Technology

Taipei Health Card / National Health Insurance IC Card Triggering Health Cloud Services



Copyright 2013 ITRI 工業技術研究院

Source: Department of Health, Taipei City Government 5

Proposing an Innovative Data Sharing Model

- A specific law for the release and use of health data from the National Health Database?
- Current Privacy Frameworks
 - anonymized or de-identification (data centric approach)
 - HIPPA (remove identifiers); Differential Privacy (adding noises)
- Community-based data sharing model
 - members are also data curators (data subject approach)
 - they are entitled to decide how they would like their data to be used
 - transparency, notification, self-governance, accountability
 - privacy impact assessment
 - ex: rare disease groups

Thank you for your attention!

